|Bid||6.26 x 800|
|Ask||6.36 x 1400|
|Day's Range||6.26 - 6.60|
|52 Week Range||1.41 - 6.97|
|Beta (5Y Monthly)||-0.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 09, 2020 - Feb 13, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Alta Fox Capital Management, LLC released its 2019 Q3 investor letter – you can download a copy here. According to the letter, the fund lost 2.21% gross and 2.10% net in the quarter. The returns compared favorably to the -2.40% return for the Russell 2000 and -5.4% return for the Russell Microcap index, but unfavorably to the S&P 500’s 1.70% […]
Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that on November 12, 2019 a United States District Court Magistrate Judge for the Southern District of New York issued a Report and Recommendation that KORU Medical’s motion to declare the patent infringement case exceptional and recoup attorneys’ fees and expenses from EMED Technologies (“EMED”) should be granted in the amount of $1,012,527.67. As previously announced, on August 30, 2019 the United States District Court for the Southern District of New York granted KORU Medical’s motion for summary judgement of non-infringement against EMED U.S. Patent 9,808,576 and dismissed the case (1:18-cv-05880-LGS) with prejudice.
Repro Med Systems, Inc. dba KORU Medical Systems today announced that management is scheduled to present at the following investor conferences in November:
Repro Med Systems, Inc. dba KORU Medical Systems today announced that it will release its financial results for the third quarter and nine months ended September 30, 2019 after the close of the financial markets on Tuesday, November 5, 2019.
Repro Med Systems, Inc. dba KORU Medical Systems today announced a poster presentation at the IgNS 2019 National Conference in Las Vegas that evaluates the performance of the Company’s HIgH-Flo Super26™ Subcutaneous Safety Needle Set against that of the Company’s standard HIgH-Flo™ 26G Needle Set in areas including patient infusion time, tolerability, comfort, and overall satisfaction.